Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-27

Reporting Person: Nanodimension Management Ltd (10% Owner)
Reporting Person: Nanodimension Limited Partnership (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-27	Common Stock	C	637790	—	Acquired	660957	Indirect
2016-06-27	Common Stock	P	385000	$14.00	Acquired	1045957	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-27	Series B Convertible Preferred Stock	$	C	315729	Disposed		Common Stock (315729)	Indirect
2016-06-27	Series C Convertible Preferred Stock	$	C	94183	Disposed		Common Stock (94183)	Indirect
2016-06-27	Series D Convertible Preferred Stock	$	C	83596	Disposed		Common Stock (83596)	Indirect
2016-06-27	Series E Convertible Preferred Stock	$	C	93078	Disposed		Common Stock (144282)	Indirect

Footnotes

F1: Held by NanoDimension L.P. ("ND LP).

F2: Consists of 660,957 shares held by ND LP, 350,000 shares held by NanoDimension L.P. II ("NDLP2") and 35,000 shares held by NanoDimension Management Limited ("ND GP").

F3: ND GP serves as the general partner of ND LP and possesses the power to direct the voting and disposition of the shares owned by ND LP and may be deemed to have indirect beneficial ownership of the shares held by ND LP. NanoDimension II Mangement Limited ("NDGP2") serves as the general partner of NDLP2 and possesses the power to direct the voting and disposition of the shares owned by NDLP2 and may be deemed to have indirect beneficial ownership of the shares held by NDLP2. ND GP and NDGP2 disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. Jonathan Nicholson and Richard Coles are the members of the board of directors of ND GP and NDGP2 and share voting and dispositive power over the shares held by ND LP and NDLP2. Each reporting person disclaims beneficial ownership of the securities reported herein, except to the extent of their respective pecuniary interest therein.

F4: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F5: The Series E Convertible Preferred Stock is convertible at any time, at the holder's election and has no expiration date. The Series E Convertible Preferred Stock automatically converted into common stock on an approximately 1-for-1.550115 basis upon the closing of the Issuer's initial public offering.